Low Dose Dasatinib (50 mg Daily) as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

Chronic Myelogenous Leukemia Clinical Trial

Official title:

Randomized, Open-Label, Phase II, Multicenter, Multi-Country Study to Evaluate Safety and Efficacy of Dasatinib 50 mg in First-Line Treatment of Early Chronic Phase Chronic Myeloid Leukemia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03625388
• Other study ID #: LPI-JOR-LEB-KSA-TUN-2017-01
• Status: Completed
• Phase: Phase 2
• Start date: November 5, 2018
• Est. completion date: July 22, 2023

Study information

• Verified date: September 2023
• Source: Hikma Pharmaceuticals LLC
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this multicenter randomized study is to compare efficacy and safety of dasatinib 50 mg once daily and dasatinib 100 mg once daily in patients with early chronic phase (CP) chronic myeloid leukemia (CML)

Description:

A multicenter, prospective, open-label, randomized Phase II study to compare efficacy by measuring rates of major molecular response (MMR) at 12 months in patients with Ph+ chronic phase (CP) chronic myeloid leukemia (CML) randomized to receive either dasatinib 50 mg QD or dasatinib 100 mg QD. Approximately 100 patients are expected to be randomized. The duration of patient participation will be 18 months

Recruitment information / eligibility

• Status: Completed
• Enrollment: 56
• Est. completion date: July 22, 2023
• Est. primary completion date: July 22, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age = 18 years.

2. Diagnosis of Ph+ or BCR-ABL positive CML in early CP (i.e. time from diagnosis <12 months). Except for hydroxyurea and/or 1-2 doses of cytarabine (up to 6g/m2 total), patients must have received no or minimal prior therapy, defined as 30 days of prior approved tyrosine kinase inhibitor (TKI).

3. Clonal evolution defined as the presence of additional chromosomal abnormalities other than the Ph-chromosome has been historically included as a criterion of accelerated phase (AP). However, patients with clonal evolution as the only criterion of AP have a significantly better prognosis, and when present at diagnosis may not impact the prognosis at all. Thus, patients with clonal evolution and no other criteria for AP will be eligible for this study.

4. ECOG performance of 0-2.

5. Adequate end organ function defined as the following: total bilirubin <1.5x ULN (unless secondary to Gilbert's disease, in which case it should be <2.5x ULN), SGPT <2.5x ULN, creatinine <1.5x ULN.

6. Patients must sign an informed consent form (ICF) indicating they are aware of the investigational nature of this study, in keeping with the policies of the hospital

Exclusion Criteria:

1. NYHA cardiac class 3-4 heart disease

2. Cardiac symptoms - Patients meeting the following criteria are not eligible unless cleared by a cardiologist:

1. Uncontrolled angina within 3 months

2. Diagnosed or suspected congenital long QT syndrome

3. Any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or torsades de pointes)

4. Prolonged QTc interval on pre-entry electrocardiogram (>460 msec)

3. History of significant bleeding disorder unrelated to cancer including:

1. Diagnosed congenital bleeding disorders (e.g. Von Willebrand's disease)

2. Diagnosed acquired bleeding disorder within one year (e.g. acquired anti-factor VIII antibodies)

3. Isolated thrombocytopenia without recurrent bleeding episodes shall be considered eligible for study entry

4. Patients with active uncontrolled psychiatric disorders including: psychosis, major depression, and bipolar disorders

5. Women of pregnancy potential must practice an effective method of birth control, unless otherwise instructed, during the course of the study in a manner such that risk of failure is minimized

1. Prior to study enrollment, women of childbearing potential (WOCBP) must be advised of the importance of avoiding pregnancy during study participation and the potential risk factors for an unintentional pregnancy

2. Postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential

3. Women must continue birth control for the duration of the study and at least 3 months after the last dose of study drug

6. Pregnant or breast-feeding women are excluded

a. All WOCBP must have a negative pregnancy test prior to first receiving the study drug. If the pregnancy test is positive, the patient must not receive the study drug and must not be enrolled in the study.

7. Patients in late chronic phase (i.e. time from diagnosis to treatment >12 months), accelerated phase (except as noted in inclusion criteria 2) or blast phase are excluded.

Related Conditions & MeSH terms

• Chronic Myelogenous Leukemia
• Leukemia
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive
• Leukemia, Myeloid
• Leukemia, Myeloid, Chronic-Phase

Intervention

Drug:
• Dasatinib
Film coated tablet contains dasatinib monohydrate

Locations

Country	Name	City	State
Jordan	Jordan University Hospital (JUH)	Amman
Jordan	King Hussein Cancer Center (KHCC)	Amman
Lebanon	American University of Beirut Medical Center (AUBMC)	Beirut
Saudi Arabia	The King Faisal Specialist Hospital and Research Centre (KFSH&RC)	Riyadh
Tunisia	Aziza Othmana Hospital	Tunis

Sponsors (1)

Lead Sponsor	Collaborator
Hikma Pharmaceuticals LLC

Countries where clinical trial is conducted

Jordan,  Lebanon,  Saudi Arabia,  Tunisia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of patients who achieve and maintain MMR at 12 months using RQ-PCR test	Major molecular response (MMR) is defined as BCR-ABL1 = 0.1%	12 months
Secondary	Incidence of adverse events (AEs) and serious adverse events (SAEs) to dasatinib	Evaluation of adverse events (AEs), serious AEs (SAEs), and clinically relevant changes in laboratory tests according to laboratory reference ranges	18 months
Secondary	Transformation free survival (TFS) in eligible patients randomized to dasatinib 50 mg or dasatinib 100 mg treatment arms	Transformation free survival was measured from the start of therapy to the date of transformation to accelerated or blastic phases while on therapy or to the date of last follow-up.	18 months
Secondary	Event free survival (EFS)	EFS is measured from the start of treatment to the date of any of the following events : loss of CHR, loss of CCyR or MCyR, dose escalation, discontinuation of therapy for toxicity or lack of efficacy, progression to AP or BP, or death from any cause at any time	18 months
Secondary	Blastic phase (BP) transformation	BP is defined as the presence of 30% blasts or more in the peripheral blood or bone marrow	18 months
Secondary	Overall survival	Overall survival time is defined as the time from date of randomization until the date of death from any cause at any time or date of last follow up	18 months
Secondary	Proportion of patients with Complete cytogenetic response (CCyR) at 12 months	defined as 0% Ph+ metaphases, or FISH =2%, or BCR-ABL transcripts (IS) =1%	12 months
Secondary	Proportion of patients with MR 4.5 at 18 months	(BCR-ABL transcripts = 0.0032%)	18 months
Secondary	Health-Related Quality of Life (HRQoL): EORTC QOLCML24	Mean change in Health-Related Quality of Life (HRQoL) utilizing EORTC QOLCML24 questionnaire throughout treatment visits	18 months
Secondary	Frequency of not taking the medications as prescribed	Evaluated by identifying the frequency of not taking the medications as prescribed and the reasons. The decision on non-compliance is based on the treating physician's judgment.	18 months